Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
Wegovy will ship directly to eligible patients through NovoCare, an online pharmacy established by Novo Nordisk. The product’s price matches a recent price cut for Zepbound offered by Eli Lilly through its own direct-to-patient online platform.
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Novo Nordisk’s monlunabant showed signs of neuropsychiatric side effects in a mid-stage diabetic kidney disease study, despite a drug design intended to favor hitting its target receptor in peripheral tissues rather than the brain. Neuro effects were also reported last year in a Phase 2 test of this pill in obesity.
Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next-generation obesity drugs. Analysts say the lack of safety and tolerability details make it difficult to fully assess the preliminary Phase 1b/2a results.
Thomas Senderovitz, senior vice president of data science at Novo Nordisk, challenges conventional notions about AI and the need for humans in the loop.
Many healthcare executives are applauding the list of additional drugs chosen for the Medicare Drug Price Negotiation Program, while some drug companies are opposing it.
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
Novo Nordisk’s new Denmark site will produce drugs for rare diseases, such as hemophilias. Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings’ acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications.
The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk's Wegovy.
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications.
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.
Novo Nordisk’s Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025.